Dominari (NASDAQ:DOMH) COO Christopher Franklin Devall Sells 140,000 Shares

Dominari Holdings Inc. (NASDAQ:DOMH) COO Christopher Franklin Devall sold 140,000 shares of the firm’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $3.82, for a total transaction of $534,800.00. Following the completion of the transaction, the chief operating officer directly owned 190,702 shares of the company’s stock, valued at approximately $728,481.64. This represents a 42.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Christopher Franklin Devall also recently made the following trade(s):

• On Wednesday, December 3rd, Christopher Franklin Devall sold 40,000 shares of Dominari stock. The shares were sold at an average price of $4.22, for a total transaction of $168,800.00.

Dominari Stock Performance

DOMH stock traded down $0.30 during midday trading on Friday, reaching $3.89. The stock had a trading volume of 740,715 shares, compared to its average volume of 220,190. The firm has a fifty day simple moving average of $5.41 and a two-hundred day simple moving average of $5.52. Dominari Holdings Inc. has a 52-week low of $0.83 and a 52-week high of $13.58. The stock has a market cap of $62.28 million, a PE ratio of 0.70 and a beta of 0.68.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on DOMH. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Dominari in a report on Tuesday. Wall Street Zen lowered shares of Dominari from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Dominari presently has a consensus rating of “Hold”.

Institutional Trading of Dominari

Several hedge funds and other institutional investors have recently bought and sold shares of DOMH. Vanguard Group Inc. raised its position in Dominari by 8.0% during the third quarter. Vanguard Group Inc. now owns 345,896 shares of the company’s stock valued at $2,452,000 after acquiring an additional 25,694 shares in the last quarter. Connective Capital Management LLC grew its stake in shares of Dominari by 26.2% during the 3rd quarter. Connective Capital Management LLC now owns 335,273 shares of the company’s stock worth $2,377,000 after purchasing an additional 69,545 shares during the period. Two Sigma Investments LP purchased a new position in shares of Dominari during the 3rd quarter valued at approximately $771,000. Geode Capital Management LLC lifted its stake in shares of Dominari by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 66,283 shares of the company’s stock valued at $361,000 after purchasing an additional 1,866 shares during the period. Finally, Millennium Management LLC purchased a new stake in Dominari during the third quarter worth $213,000. 42.48% of the stock is owned by institutional investors and hedge funds.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.